Spectrum drops experimental drug for enlarged prostate

01/27/2010 | Reuters

Spectrum Pharmaceuticals decided to abandon development of ozarelix, its experimental treatment for benign prostatic hypertrophy, after the drug fared poorly in a midstage clinical trial. The move is expected to save Spectrum more than $40 million.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care